20
Participants
Start Date
February 18, 2022
Primary Completion Date
February 28, 2026
Study Completion Date
February 28, 2026
Obinutuzumab
Each patient will be treated for 1 month and received a total of 3 doses. The first dose of Obinutuzumab (1000 mg) will be split in two separate infusions; on the first day each patient will receive 100 mg and the next day 900 mg of Obinutuzumab. Obinutuzumab (1000 mg) will be also administered at two and four weeks after the first infusion. Obinutuzumab will be administered after standard premedication.
"Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò", Ranica
ASST HPG23 - Unità di Nefrologia, Bergamo
Roche Pharma AG
INDUSTRY
Mario Negri Institute for Pharmacological Research
OTHER